Login
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc.

spyre.com

What Do They Do?

Develops investigational antibodies and antibody combinations for people with inflammatory bowel disease and rheumatic diseases.

Who Are Their Customers?

Immedica licensed pegzilarginase commercialization rights in Europe and specified Middle Eastern countries; Spyre later sold Immedica global rights to the product.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −760% (Loss)
vs −$11.2M in Q3 FY2025
  • Jun 1, 2026 SPY003 license expands beyond inflammatory bowel disease The license covers all therapeutic, prophylactic, palliative and diagnostic uses, but limits combination dosing outside inflammatory bowel disease until June 1, 2028 and monotherapy until June 1, 2030.

From enzymes to antibodies The business moved from developing human enzyme therapies for rare metabolic diseases to developing long-acting antibodies and antibody combinations for inflammatory bowel and rheumatic diseases.

Who Do They Compete With?

Competes with AbbVie, Johnson & Johnson, Lilly, Takeda, Pfizer, Bristol Myers Squibb, Merck, Roche, Roivant, Sanofi, Teva, Innovent, Gilead, Palisade Bio, Sorriso, Earendil, Simcere, Boehringer Ingelheim, Xencor, and UCB

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support